Nuvo Pharmaceuticals(TM) Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
CNW Group - Wed Jul 13, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains. Topline results of the Trial are expected to be available in late Q2 or early Q3 2017. The Trial is subject to approval by German regulatory authorities and the ethical review committee. Pennsaid 2% is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of the pain of osteoarthritis of the knee(s). The Trial will be conducted to support regulatory applications for marketing approval of Pennsaid 2% for the treatment of acute pain in the E.U., Canada and Australia. The Company believes that most other jurisdictions will base their marketing approval on existing data, including the current U.S. FDA approval of Pennsaid 2% and will not require additional clinical efficacy data. The Trial will cost approximately CDN$1.5 million spread over the second half of 2016 and the first half of 2017. The Company believes that potential revenue to be generated by the Trial far exceeds its modest cost.
NRI.TO: 6.93 (-0.07), HZNP: 19.29 (-0.33)
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 19.29 (-0.33)
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 19.29 (-0.33)
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
PR Newswire - Wed May 11, 4:00PM CDT
Revenue and gross margin increase - - Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
NRI.TO: 6.93 (-0.07), HZNP: 19.29 (-0.33)
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development
PR Newswire - Mon Apr 04, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced that Jesse Ledger has been appointed to the newly created position of Vice President, Business Development. Mr. Ledger will be responsible for all business development activities with an initial focus on maximizing the value of the Company's Pennsaid 2% franchise through global out-licensing.
NRI.TO: 6.93 (-0.07), HZNP: 19.29 (-0.33), ARLZ: 3.50 (-0.03), POZN: 5.94 (-0.43)